Financial Data and Key Metrics Changes - Q4 2025 total revenue was $163 million, down 12% year-over-year, with clinical revenue growing by 32% and behavioral revenue declining by 17% [59] - Adjusted gross margin remained near record highs at 74.4% in Q4, slightly declining compared to Q3 due to seasonal staffing and a shift towards clinical services [60] - Adjusted EBITDA for Q4 was $18 million, reflecting an adjusted EBITDA margin of 11.1% [62] Business Line Data and Key Metrics Changes - End-of-period clinical subscribers reached 130,000 at the end of Q4, with expectations to end Q1 2026 with approximately 200,000 subscribers, indicating nearly 100% year-over-year growth [50][51] - End-of-period behavioral subscribers were 2.6 million at the end of Q4 2025, with an expected decline to approximately 2.45 million by the end of Q1 2026, representing a 26% year-over-year decrease [52][55] - Monthly subscription revenue per average subscriber (ARPU) increased by 8% year-over-year to $18.73 in Q4, with clinical ARPU being over four times higher than behavioral ARPU [57] Market Data and Key Metrics Changes - Approximately 10 million Americans are estimated to be on GLP-1 medications, with projections suggesting this could rise to between 25 and 50 million by 2030 [17] - The proportion of first-time Weight Watchers members in the U.S. increased to 35% across all programs in January, with 50% of new Med+ members being new to the Weight Watchers brand [39] Company Strategy and Development Direction - The company is transitioning from a behavioral subscription model to an integrated weight health ecosystem that includes medication access and clinical care [18] - Strategic focus areas include enhancing member experience, expanding medical offerings, and modernizing technology infrastructure [24][25] - The company aims to leverage its brand trust and scientific credibility while modernizing its approach to meet today's consumer needs [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to succeed post-reorganization, emphasizing the importance of integrating behavioral and clinical offerings [45][46] - The company acknowledges the challenges posed by the growing adoption of GLP-1 medications and aims to adapt its business model accordingly [40] - Management highlighted the importance of member engagement and the positive trends in member acquisition and retention [41][44] Other Important Information - The company eliminated over $1.1 billion of debt through financial reorganization, allowing for a refocus on investment and growth [48] - Marketing expenses in Q4 were 40% of revenue, reflecting increased spending to raise awareness of the Med+ offering [61] - The company expects revenue for fiscal year 2026 to be in the range of $620 million to $635 million, with adjusted EBITDA projected between $105 million and $115 million [70] Q&A Session Summary Question: Changes in demand for weight loss medications - Management noted a consistent trend of increasing consumer interest and adoption of GLP-1 medications, particularly with the introduction of lower-priced oral options [77][78] Question: Profile of new members and demographic changes - Management indicated that they are seeing younger members and lapsed members returning, with efforts to modernize the brand contributing to this trend [98][100] Question: Pricing strategy and promotional activities - Management discussed a shift in pricing strategy allowing long-term commitments to renew, which may impact ARPU but aims to stabilize membership [113][116] Question: B2B initiative and growth expectations - Management expressed enthusiasm about the B2B pipeline and partnerships, particularly with UnitedHealth Group, indicating a focus on expanding employer relationships [120][122]